Acelarin First Line Randomised Pancreatic Study

NCT03610100 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

SUSPENDED

Status

328

Enrollment

OTHER

Sponsor class

Stopped Suspended to recruitment following TSC review on efficacy and toxicities

Conditions

Pancreatic Acinar Carcinoma
Pancreatic Neoplasms

Interventions

DRUG: Acelarin
DRUG: Gemcitabine

Sponsor

The Clatterbridge Cancer Centre NHS Foundation Trust

Collaborators

[object Object]
[object Object]